Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,295 papers from all fields of science
Search
Sign In
Create Free Account
Glioblastoma Cancer Vaccine ERC1671
Known as:
ERC-1671
, ERC1671
, Gliovac
A cancer vaccine composed of a combination of autologous glioblastoma (GBM) tumor cells, allogeneic GBM tumor cells, generated from three different…
Expand
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
HOUT-17. A PRELIMINARY DATA REPORT ON A PHASE 2 STUDY OF ERC1671 IN RECURRENT GLIOBLASTOMA
D. Bota
,
Jinah Chung
,
+6 authors
A. Stathopoulos
2017
Corpus ID: 79828998
2016
2016
ATIM-20. A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE ERC-1671 (GLIOVAC) VACCINE IN COMBINATION WITH BEVACIZUMAB (BEV) IN RECURRENT GBM PATIENTS: SAFETY LEAD-IN ANALYSIS
D. Bota
,
J. Carrillo
,
+6 authors
A. Stathopoulos
2016
Corpus ID: 78294147
2015
2015
Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report.
D. Bota
,
D. Alexandru-Abrams
,
+6 authors
A. Stathopoulos
The Permanente Journal
2015
Corpus ID: 26697732
Glioblastoma multiforme is a highy aggressive tumor that recurs despite resection, focal beam radiation, and temozolamide…
Expand
2015
2015
A personalized immunotherapeutic vaccine (Gliovac Or ERC1671) against recurrent glioblastoma multiforme (GBM)
V. Schijns
,
D. Bota
,
A. Stathopoulos
2015
Corpus ID: 53360192
Patients suffering from a glioblastoma multiforme (GBM) present a very poor prognostic. GBM is the most malignant glioma with a…
Expand
2012
2012
FIRST REPORT OF ERC-1671 (GLIOVAC) VACCINE USE IN GLIOBLASTOMA PATIENTS WITH RECURRENT DISEASE
D. Bota
,
Chrystel M Pretto
,
+5 authors
A. Stathopoulos
2012
Corpus ID: 190867828
Author(s): Bota, Daniela A; Pretto, Chrystel; Hantos, Peter; Hofman, Florence M; Chen, Thomas C; Carrillo, Jose A; Schijns…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE